Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors

Multiple Cancer Types

The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 when administered as a single agent and in combination with nivolumab and determine the recommended Phase 2 dose (RP2D) of ASP1948 when administered as a single agent and in combination with nivolumab. This study will also evaluate the antitumor effect of ASP1948 when administered as a single agent and in combination with nivolumab.
Miscellaneous, Phase I
I
Horn, Leora
NCT03565445
VICCPHI1907

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: